Fangping is CEO at Speedwell Bio. She holds a degree in Medicine and two master degrees in Molecular Biology (Peking Union Medical College) and Biomedical Engineering (UPenn) with extensive experience in muscle metabolism and cancer metabolism. After spending four years at GlaxoSmithKline in drug discovery and seven years at Genetron Health leading the RTP group in development of molecular tests for oncology, she confounded Speedwell with Dr. Moore and Dr. Kumar.
John is the Scientific Director at Speedwell Bio. He spent 23 years in R&D at GlaxoSmithKline, the last 4 years as Director of the Experimental Biology group in RTP, participating in and leading projects in drug discovery, phenotypic assay development, and target validation. John received his bachelor’s degree from the University of Virginia, his Ph.D. from University of Minnesota, and his postdoctoral training in genetics at the University of California, Berkeley.